Aptevo Therapeutics Inc
NASDAQ:APVO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Aptevo Therapeutics Inc
NASDAQ:APVO
|
US |
|
S
|
Shanxi Antai Group Co Ltd
SSE:600408
|
CN |
|
Biome Technologies PLC
LSE:BIOM
|
UK |
|
FiEE Inc
NASDAQ:FIEE
|
US |
|
C
|
Cabbacis Inc
OTC:CABI
|
US |
Balance Sheet
Balance Sheet Decomposition
Aptevo Therapeutics Inc
Aptevo Therapeutics Inc
Balance Sheet
Aptevo Therapeutics Inc
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||
| Cash & Cash Equivalents |
4
|
5
|
10
|
7
|
31
|
12
|
40
|
45
|
23
|
17
|
9
|
22
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
5
|
5
|
4
|
1
|
4
|
1
|
1
|
|
| Cash Equivalents |
4
|
5
|
10
|
7
|
31
|
7
|
35
|
41
|
22
|
13
|
8
|
20
|
|
| Short-Term Investments |
0
|
0
|
45
|
74
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
15
|
8
|
0
|
2
|
5
|
7
|
2
|
4
|
3
|
0
|
0
|
0
|
|
| Accounts Receivables |
14
|
6
|
0
|
2
|
5
|
7
|
2
|
4
|
3
|
0
|
0
|
0
|
|
| Other Receivables |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
18
|
20
|
0
|
1
|
2
|
6
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
5
|
2
|
16
|
11
|
11
|
4
|
5
|
4
|
2
|
2
|
2
|
1
|
|
| Total Current Assets |
42
|
35
|
71
|
95
|
49
|
30
|
47
|
53
|
27
|
19
|
11
|
23
|
|
| PP&E Net |
3
|
4
|
6
|
6
|
5
|
8
|
6
|
4
|
7
|
6
|
5
|
4
|
|
| PP&E Gross |
3
|
4
|
6
|
6
|
5
|
8
|
6
|
4
|
7
|
6
|
5
|
4
|
|
| Accumulated Depreciation |
5
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
13
|
14
|
14
|
14
|
|
| Intangible Assets |
61
|
59
|
7
|
6
|
5
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Goodwill |
14
|
29
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
8
|
10
|
8
|
11
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Other Assets |
14
|
29
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
120
N/A
|
128
+6%
|
92
-28%
|
117
+27%
|
67
-42%
|
53
-21%
|
54
+0%
|
57
+6%
|
34
-40%
|
25
-27%
|
16
-37%
|
27
+74%
|
|
| Liabilities | |||||||||||||
| Accounts Payable |
11
|
10
|
11
|
7
|
12
|
13
|
6
|
3
|
3
|
4
|
3
|
1
|
|
| Accrued Liabilities |
4
|
3
|
4
|
5
|
4
|
4
|
4
|
3
|
3
|
3
|
3
|
5
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
3
|
0
|
20
|
5
|
12
|
2
|
0
|
0
|
0
|
|
| Other Current Liabilities |
4
|
7
|
5
|
3
|
2
|
1
|
0
|
17
|
1
|
0
|
0
|
0
|
|
| Total Current Liabilities |
20
|
20
|
20
|
19
|
18
|
38
|
15
|
35
|
9
|
7
|
6
|
6
|
|
| Long-Term Debt |
0
|
0
|
18
|
16
|
19
|
0
|
20
|
4
|
1
|
0
|
0
|
0
|
|
| Deferred Income Tax |
2
|
16
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
4
|
3
|
3
|
1
|
0
|
3
|
2
|
17
|
6
|
5
|
5
|
4
|
|
| Total Liabilities |
25
N/A
|
39
+54%
|
41
+5%
|
35
-15%
|
37
+6%
|
42
+12%
|
37
-11%
|
55
+50%
|
16
-71%
|
13
-22%
|
11
-14%
|
10
-9%
|
|
| Equity | |||||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
173
|
232
|
81
|
74
|
127
|
168
|
186
|
214
|
206
|
223
|
248
|
275
|
|
| Additional Paid In Capital |
0
|
0
|
151
|
156
|
158
|
180
|
202
|
215
|
224
|
236
|
252
|
292
|
|
| Other Equity |
267
|
321
|
20
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
95
N/A
|
89
-6%
|
51
-43%
|
82
+62%
|
30
-63%
|
12
-61%
|
17
+40%
|
1
-93%
|
18
+1 378%
|
12
-32%
|
5
-61%
|
17
+266%
|
|
| Total Liabilities & Equity |
120
N/A
|
128
+6%
|
92
-28%
|
117
+27%
|
67
-42%
|
53
-21%
|
54
+0%
|
57
+6%
|
34
-40%
|
25
-27%
|
16
-37%
|
27
+74%
|
|
| Shares Outstanding | |||||||||||||
| Common Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|